Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases

JAMA Oncol. 2022 Nov 1;8(11):1700. doi: 10.1001/jamaoncol.2022.4343.
No abstract available

Publication types

  • Letter

MeSH terms

  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / secondary
  • Breast Neoplasms* / pathology
  • Female
  • Heterocyclic Compounds, 4 or More Rings / adverse effects
  • Humans
  • Polyethylene Glycols / adverse effects

Substances

  • etirinotecan pegol
  • Heterocyclic Compounds, 4 or More Rings
  • Polyethylene Glycols